New Enterprise Associates
VC Fund
Menlo Park, United States
New Enterprise Associates is a venture capital firm that invests in technology and healthcare startups. The firm engages with entrepreneurs at various stages of business development, providing support from initial funding to public offerings. The company focuses on the technology and healthcare industries.
- Total investments:
- 2087
- Last investment:
- Lead investor:
- 39%
- Fund size:
- $468M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries New Enterprise Associates invests in
Stages New Enterprise Associates invests in
Countries New Enterprise Associates invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 51 contacts → | |||
Round size
- Series A
- $6M–$55M
- Series B
- $10M–$85M
- Series C
- $15M–$102M
Investment Focus
Industry
- Software 267 (13%)
- Health Care 203 (10%)
- Biotechnology 163 (8%)
- Artificial Intelligence 121 (6%)
- Information Technology 108 (5%)
Stage
- Series A 368 (18%)
- Series B 360 (17%)
- Series C 251 (12%)
- Seed 206 (10%)
- Series D 132 (6%)
Country
- United States 835 (40%)
- China 21 (1%)
- India 19 (1%)
- United Kingdom 16 (1%)
- Canada 14 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alex Sharata
Associate
|
Associate | Total investments: 2 | Find email | |
Anthony Florence
General Partner
|
General Partner | Total investments: 61 | Find email | |
Bala Deshpande
Sr. Managing Director, India
|
Sr. Managing Director, India | Total investments: 7 | Find email | |
Hilarie Koplow-McAdams
Venture Partner
|
Venture Partner | Total investments: 14 | Find email | |
Jay Graf
Venture Partner
|
Venture Partner | Total investments: 11 | Find email | |
| See all 51 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Basalt Health is a healthcare technology company that provides an AI-powered assistant for clinical teams. | $20M / Series A / Sep 24, 2026 | ||
| Factory functions within integrated development environments, command line interfaces, and continuous integration pipelines. The technology allows for the delegation of technical tasks, including code refactors, system migrations, and incident responses. These digital agents also perform automated code reviews and facilitate the maintenance ofbuilds during the development process. Integration extends to communication platforms and project management software, allowing users to trigger actions from various interfaces. The system supports the parallelization of agents to manage software updates and maintenance across multiple operating systems. | $200M / Venture - Series Unknown / Sep 15, 2026 | ||
| LLM Inference Hardware | $500M / Series C / Sep 10, 2026 | ||
| Latitude is working on a global payments system that links stablecoin-based settlement with local currency payout systems. | $35M / Series A / Sep 09, 2026 | ||
CaMaRa
|
CaMaRa is a biotechnology company developing new medicines for cardiometabolic conditions, including obesity, diabetes and kidney disease. | Seed / Sep 09, 2026 | |
| Tectora Therapeutics develops oral medicines designed to treat immune-mediated diseases, specifically focusing on immunology and inflammation. The company co-develops its pipeline by utilizing advanced computational drug discovery platforms and preclinical capabilities. Its core value proposition centers on translating clinically validated biologyinto oral small-molecule therapies to address significant unmet patient needs. | $55M / Series A / Sep 09, 2026 | ||
| Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $66M / Series D / Aug 18, 2026 | ||
| Think it, speak it, send it. Effortless voice dictation for Mac and now Windows! | $280M / Series B / Aug 17, 2026 | ||
| Databricks is a software platform that helps its customers unify their analytics across the business, data science, and data engineering. It also provides a Unified Analytics Platform for data science teams to collaborate with data engineering and lines of business to build data products. The company was founded in 2013 and is headquartered inSan Francisco, California. | $5B / Private Equity / Aug 13, 2026 | ||
| Horizon3.ai's mission is to help you find and fix your attack vectors before criminals exploit them. NodeZero, our automated penetration testing solution, enables organizations to continuously assess the security posture of their enterprise, including external, identity, on-prem, IoT, and cloud attack surfaces. Like APTs, ransomware, andother threat actors, our algorithms discover and fingerprint your attack surface, identifying the ways exploitable vulnerabilities, misconfigurations, harvested credentials, and dangerous product defaults can be chained together to facilitate a compromise. NodeZero is a true self-service SaaS offering that is safe to run in production and requires no persistent or credentialed agents. You will see your enterprise through the eyes of the attacker, identify your ineffective security controls, and ensure your limited resources are spent fixing problems that can actually be exploited. Founded in 2019 by industry, US Special Operations, and US National Security veterans, Horizon3.ai is headquartered in San Francisco, CA, and made in the USA. | $250M / Series E / Aug 03, 2026 | ||
| See all 2087 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does New Enterprise Associates invest in?
New Enterprise Associates invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 2,087 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is New Enterprise Associates's check size?
New Enterprise Associates typically joins rounds of $6M–$55M at Series A, $10M–$85M at Series B and $15M–$102M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds New Enterprise Associates participates in.
How do I contact New Enterprise Associates?
Public channels for New Enterprise Associates include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at New Enterprise Associates?
The team at New Enterprise Associates includes Alex Sharata (Associate), Anthony Florence (General Partner) and Bala Deshpande (Sr. Managing Director, India), among 51 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
